Genelux (GNLX) vs Immunic (IMUX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Immunic (IMUX) has outperformed Genelux (GNLX) over the past year, losing 15.8% versus a loss of 47.4%. Genelux is the larger company by market cap ($113.1 million vs $103.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GNLX | IMUX |
|---|---|---|
| Share price | $2.50 | $7.56 |
| Market cap | $113.11M | $103.15M |
| 1-day change | -0.79% | -0.92% |
| YTD return | -42.66% | +41.57% |
| 1-year return | -47.37% | -15.81% |
| 5-year return | — | -91.28% |
| EPS (TTM) | $-0.86 | $-3.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.54 | $17.43 |
| 52-week low | $2.29 | $5.06 |
| Distance from 52-week high | -70.71% | -56.63% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +653.20% | +469.97% |
| Average volume | 276.16K | 284.68K |
| Shares outstanding | 45.25M | 13.64M |
| Employees | 25 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMUX has outperformed GNLX by 31.6 percentage points over the past year.
About Genelux
GNLX stock →Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
About Immunic
IMUX stock →Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
GNLX vs IMUX FAQ
Which is bigger, Genelux or Immunic?
Genelux (GNLX) is larger, with a market capitalization of $113.11M compared with $103.15M for Immunic (IMUX).
Which stock has performed better over the past year, GNLX or IMUX?
IMUX returned -15.81% over the past 12 months, compared with -47.37% for GNLX (price return, excluding dividends). Past performance does not predict future results.
Are Genelux and Immunic in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.